Wall Street brokerages forecast that Strongbridge Biopharma plc (NASDAQ:SBBP) will announce earnings of ($0.59) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Strongbridge Biopharma’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.46). Strongbridge Biopharma posted earnings per share of ($0.31) during the same quarter last year, which would suggest a negative year-over-year growth rate of 90.3%. The firm is scheduled to report its next quarterly earnings report on Monday, March 11th.
According to Zacks, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.74) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.59). For the next year, analysts forecast that the company will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.15) to ($0.82). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Strongbridge Biopharma.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.06). The company had revenue of $5.35 million during the quarter, compared to analyst estimates of $5.48 million.
Shares of SBBP stock traded up $0.09 on Friday, hitting $5.10. 123,661 shares of the company’s stock were exchanged, compared to its average volume of 451,925. The company has a quick ratio of 3.11, a current ratio of 3.38 and a debt-to-equity ratio of 8.76. Strongbridge Biopharma has a 12 month low of $3.85 and a 12 month high of $9.25. The company has a market cap of $244.29 million, a P/E ratio of -3.52 and a beta of -0.36.
A number of institutional investors have recently bought and sold shares of SBBP. Millennium Management LLC raised its position in Strongbridge Biopharma by 380.4% in the second quarter. Millennium Management LLC now owns 662,419 shares of the biotechnology company’s stock valued at $3,975,000 after purchasing an additional 524,539 shares during the last quarter. Sphera Funds Management LTD. raised its position in Strongbridge Biopharma by 74.9% in the third quarter. Sphera Funds Management LTD. now owns 1,179,010 shares of the biotechnology company’s stock valued at $5,718,000 after purchasing an additional 505,014 shares during the last quarter. Prosight Management LP bought a new position in Strongbridge Biopharma in the third quarter valued at about $2,056,000. BlackRock Inc. raised its position in Strongbridge Biopharma by 25.4% in the first quarter. BlackRock Inc. now owns 1,795,693 shares of the biotechnology company’s stock valued at $15,892,000 after purchasing an additional 363,328 shares during the last quarter. Finally, Opaleye Management Inc. raised its position in Strongbridge Biopharma by 15.1% in the second quarter. Opaleye Management Inc. now owns 1,830,000 shares of the biotechnology company’s stock valued at $10,980,000 after purchasing an additional 240,000 shares during the last quarter. Hedge funds and other institutional investors own 67.33% of the company’s stock.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
See Also: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.